CN103772405A - 双苄基四氢异喹啉类生物碱及其制备方法和应用 - Google Patents

双苄基四氢异喹啉类生物碱及其制备方法和应用 Download PDF

Info

Publication number
CN103772405A
CN103772405A CN201210414509.1A CN201210414509A CN103772405A CN 103772405 A CN103772405 A CN 103772405A CN 201210414509 A CN201210414509 A CN 201210414509A CN 103772405 A CN103772405 A CN 103772405A
Authority
CN
China
Prior art keywords
acid
hanfangchin
phenyl
compound
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201210414509.1A
Other languages
English (en)
Other versions
CN103772405B (zh
Inventor
杨义芳
赖龙
吴春珍
胡晓
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Pharmaceutical Industry
China State Institute of Pharmaceutical Industry
Original Assignee
Shanghai Institute of Pharmaceutical Industry
China State Institute of Pharmaceutical Industry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry filed Critical Shanghai Institute of Pharmaceutical Industry
Priority to CN201210414509.1A priority Critical patent/CN103772405B/zh
Publication of CN103772405A publication Critical patent/CN103772405A/zh
Application granted granted Critical
Publication of CN103772405B publication Critical patent/CN103772405B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开如下通式I所示的化合物或其药学上可接受的盐:其中R1、R2、R3、R4和R5如说明书中所定义。本发明还公开制备所述式I化合物的方法。本发明所述式I化合物对多种肿瘤细胞株均有明显的抗肿瘤作用,可在制备治疗肿瘤药物中应用。

Description

双苄基四氢异喹啉类生物碱及其制备方法和应用
技术领域
本发明属于药物化学领域,具体涉及一类具有对肿瘤细胞株有明显的抗肿瘤作用的双苄基四氢异喹啉衍生物及其制备方法和医药用途。
背景技术
双苄基异喹啉类生物碱(Bisbenzylisoquinoline alkaloid,简称BBI)是一类在植物界分布局限、结构类型多样、生理活性广泛的天然二聚生物碱。他们中绝大多数存在于植物界中较原始的多心皮类群中(防已科、毛莨科、小檗科)。Guha等依据其结构中醚键的数目、连接位置、取代状况将其分成26个结构类型(Guha K P,and MudherjeeB.J.Nat.Prod.1979,42(1):1~84)。近年研究表明,这一类化合物在抗疟、抗炎、抗癌、心血管方面具有良好的生理活性,并且具有很好的Ca2+拮抗作用,是一类开发抗疟、抗癌,治疗心血管疾病很有前途的成分。目前已发现的BBI类天然产物约有近800种如小璧科的尖刺碱、小聚胺等,防己科的粉防己碱、海岛轮环藤碱、高阿洛莫林、蝙蝠葛碱、左旋箭毒碱,毛莫科的小巢胺、唐松草西敏碱等。粉防己碱、蝙蝠葛碱、轮环藤碱、头花千金藤碱等BBI生物碱可逆转肿瘤多药耐药性,是具有较好临床应用前途的化学增敏剂;从加勒比海背囊动物红树海鞘中提取得到的含有3个四氢异喹啉环结构的海鞘素在体内有较好的抗肿瘤活性,近来西班牙Pharmamar公司将其开发为新药Yondelis,已经在英国、瑞士和菲律宾等许多国家上市,用于治疗软组织肉瘤,另外还与强生公司合作研究其在子宫内膜癌和乳腺癌治疗方面的应用。
近来对双苄基四氢异喹啉的研究尤其是以能大量制备的汉防己甲素关于抗肿瘤方面的研究被广泛开展。在Tet的多种抗肿瘤机制中,直接细胞毒作用、诱导凋亡作用、放化疗减毒增敏、逆转耐药、正常组织的放射保护作用、抗远处转移及抗血管新生等研究最具发展前景。汉防己甲素可作为一种肿瘤细胞杀伤药,亦可作为放化疗辅助用药。(ChenYJ·Potential role of tetrandrine in cancer therapy Leuk Res〔J〕·ActaPharmacol Sin·2002,23(12):1102-6)汉防己甲素体外对小鼠艾氏腹水瘤、大鼠腹水型肝癌细胞、肝癌细胞HepG2、人鼻咽癌CNE细胞株、人肝癌细胞、Hela细胞、肉瘤S180等多种肿瘤细胞具有生长抑制作用;研究发现汉防己甲素可诱导多种肿瘤细胞凋亡,包括人白血病U937细胞、人肺癌A549细胞、人肝癌HepG-2细胞、人结肠癌HT29细胞、人恶性淋巴瘤BM13674细胞、大鼠神经胶质瘤C-6等;汉防己甲素对白血病L7721细胞、视网膜母细胞瘤HXO-Rb44细胞、人恶性胶质瘤U138MG细胞等多种肿瘤细胞具有放疗增敏作用;汉防己甲素与阿霉素或长春新碱联合用药对人乳腺癌MCF-7和MCF-7/Dox细胞株以及人鼻咽癌KB和KBv200细胞株具有体外抗肿瘤增效作用;汉防己甲素对慢性粒细胞白血病急性变白血病细胞株K562/ADM体内外均有较好的多药耐药逆转作等。
然而,对此类化合物进行结构修饰的研究并进行抗肿瘤的研究却不曾有,因此本发明旨在对具有广泛抗肿瘤活性的双苄基四氢异喹啉类生物碱进行结构修饰,并对几种肿瘤细胞株进行了细胞毒筛选。
发明内容
本发明基于目前对双苄基四氢异喹啉类生物碱抗肿瘤活性的广泛研究,但这类化合物多局限于天然产物,结构修饰和构效关系研究报告甚少。本发明以先导化合物汉防己甲素为原料,设计并制备了一系列化合物,通过体外实验进行抗肿瘤研究,以期获得活性更高的化合物供进一步的开发成新药。
因此,第一方面,本发明提供一种通式I所示的化合物或其药学上可接受的盐:
Figure BDA00002306746900031
其中:
R1、R2独立地为甲基或氢;
R3、R4独立地为甲氧基、羟基或含1-10个碳原子的直链或支链的烷氧基或酰氧基;
R5独立地为H或含1-20个碳原子的直链或支链的饱和或不饱和的烷基、环烷基、硅烷基、烷氧基或酰氧基,或者为芳香苯环或芳香杂环,其中所述苯环或杂环任选被一个或多个取代基取代;其中所述取代基为含1-20个碳原子的直链或支链的饱和或不饱和的烷基、环烷基、硅烷基、烷氧基或酰氧基或卤素原子;
其中排除R1和R2为CH3或氢;R3为OCH3或OH;R4为OCH3或OH以及R5为H、OH或OCH3的式I化合物及其盐。
根据本发明一个优选的实施方式,所述R5独立地为苯乙炔基、3,3-二甲基-丁-1-炔基、己-1-炔基、3-环戊烷-丙-1-炔基、1-氟-4-苯基乙炔基、1-叔丁基-4-苯基乙炔基、(2-吡啶基)-乙炔基、辛-1,7-二炔基、环戊基乙炔基、葵-1-炔基、3-环己烷-丙-炔基、1-甲氧基-4-苯乙炔基、苯基、4-三氟甲基苯基、4-叔丁基苯基、4-甲氧基苯基、4-氯基苯基、4-甲基苯基、2-噻吩基或5-甲氧基-2-吡啶基。
根据本发明一个优选的实施方式,通式I中C(1)和C(1’)构型为RR、SS、1S1’R或1R1’S。
根据本发明一个优选的实施方式,本发明所述的药学可接受的盐包括但不限于无机酸如盐酸、硝酸、硫酸、磷酸、氢溴酸,或者有机酸如马来酸、富马酸、柠檬酸、酒石酸、乳酸、乙酸、甲磺酸、对甲苯磺酸、己二酸、棕榈酸、单宁酸组成的盐以及通过碘或溴代烷烃在2和2′位衍生化的季铵盐。
本发明中的术语“烷基”是指C1-C20,优选C1-C10的直链或支链烷基。烷基的实例是甲基、乙基、丙基、丁基、戊基、己基等以及它们可能的异构体。
本发明中的术语“环烷基”是指C3-C20,优选C3-C10的环烷基。环烷基的实例是环丙基、环丁基、环戊基等以及它们可能的异构体。
本发明中的术语“烷氧基”是指C1-C20,优选C1-C10的烷氧基。烷氧基的实例是甲氧基、乙氧基、丙氧基等以及它们可能的异构体。
本发明中的术语“酰氧基”是指C2-C20,优选C2-C10的酰氧基。酰氧基的实例是乙酰氧基、丙酰氧基、丁酰氧基等以及它们可能的异构体。
本发明中的术语“硅烷基”是指C1-C10直链或直链取代氢的硅烷,如三甲基硅烷、三叔丁基硅烷等以及它们可能的异构体。
本发明中的术语“芳香苯环”是指C6-C14的芳基。芳基的实例是苯基或萘基。
本发明中的术语“芳香杂环”是指C3-C10的芳香杂环。芳香杂环的实例是吡啶基、噻吩基、哌嗪基、咪唑基、哌啶基、呋喃基、嘧啶基、吲哚基等。
第二方面,本发明提供制备所述通式I化合物或其药学上可接受的盐的方法,包括使5-溴代双苄基四氢异喹啉在有机磷配体和碱存在下,利用钯催化剂在有机溶剂中进行Sonogashira偶联或Suzuki偶联反应的步骤。
本发明所述的5-溴代双苄基四氢异喹啉(式II化合物)通过本领域已知方法按照以下具体步骤获得:
由式III化合物通过卤原子取代得到式II所示的中间体化合物,其中制备条件为在-15至0摄氏度冰盐浴中,缓慢将1M的溴的乙酸溶液滴入汉防己甲素的三氟乙酸水溶液中,反应时间为4小时,反应完毕用2M的氢氧化钠水溶液调PH至中性,以二氯甲烷提取并以饱和食盐水洗涤三次后无水硫酸钠干燥,以乙醚/甲醇重结晶得白色晶体。产率为95%。
上述反应的反应路线如下路线1表示:
路线1:
Figure BDA00002306746900051
R1、R2独立地为甲基或氢;
R3、R4独立地为甲氧基、羟基或含1-10个碳原子的直链或支链的烷氧基或酰氧基;
然后5-溴代双苄基四氢异喹啉(式II化合物)可以在有机磷配体和碱存在下,利用钯催化剂在有机溶剂中进行Sonogashira偶联或Suzuki偶联反应,所述Sonogashira偶联及Suzuki偶联反应的反应路线分别如下路线2和3表示:
路线2:
Figure BDA00002306746900052
上式中,R5=R+乙炔基。
R1、R2独立地为甲基或氢;
R3、R4独立地为甲氧基、羟基或含1-10个碳原子的直链或支链的烷氧基或酰氧基;
R独立地为H或含1-20个碳原子的直链或支链的饱和或不饱和的烷基、环烷基、硅烷基、烷氧基或酰氧基,或者为芳香苯环或芳香杂环,其中所述苯环或杂环任选被一个或多个取代基取代;其中所述取代基为含1-20个碳原子的直链或支链的饱和或不饱和的烷基、环烷基、硅烷基、烷氧基或酰氧基或卤素原子;
路线3:
Figure BDA00002306746900061
R1、R2独立地为甲基或氢;
R3、R4独立地为甲氧基、羟基或含1-10个碳原子的直链或支链的烷氧基或酰氧基;
R5独立地为H或含1-20个碳原子的直链或支链的饱和或不饱和的烷基、环烷基、硅烷基、烷氧基或酰氧基,或者为芳香苯环或芳香杂环,其中所述苯环或杂环任选被一个或多个取代基取代;其中所述取代基为含1-20个碳原子的直链或支链的饱和或不饱和的烷基、环烷基、硅烷基、烷氧基或酰氧基或卤素原子;
根据本发明一个优选的实施方式,所述有机磷配体可以三苯基膦(PPh3)、1,1′-双(二苯基膦)二茂铁(dppf)、(±)-2,2′-双-(二苯膦基)-1,1′-联萘(BINAP)或1,4-双二苯基膦丁烷(dppb),其用量可以为0.01-1当量。
根据本发明一个优选的实施方式,所述钯催化剂可以选自零价钯或二价钯,其用量为0.01-1当量。
根据本发明一个优选的实施方式,所述碱可以选自碳酸钠、碳酸钾、碳酸铯、氢氧化钠、氢氧化钾、三乙胺或氢氧化钡,其用量为至少1个当量。
根据本发明一个优选的实施方式,本发明在有机溶剂例如DMSO、DMF、THF、甲苯、二氧六环或乙腈中进行。反应的温度可以为60-150℃。
根据本发明一个特别优选的实施方式,Sonogashira偶联反应条件及方法主要是:将式II溶于DMSO中,加入1.2个当量的Cs2CO3(CAS:534-17-8)、2个当量的端基炔试剂,0.03个当量双三苯基膦二氯化钯(CAS:13965-03-2),在氮气保护下,100℃反应10小时,过滤后加入20倍当量氨水,饱和食盐水洗涤三次后无水硫酸钠干燥后以乙醚甲醇重结晶得产物。
根据本发明一个特别优选的实施方式,Suzuki偶联反应反应条件及方法主要是:将式II溶于甲苯或1,4-二氧六环中,加入溶剂等量的2M的碳酸钠水溶液,2个当量的硼酸试剂,加入0.03当量的Pd(dppf)Cl2([1,1’-双(二苯基磷)二茂铁]二氯化钯,(CAS:72287-26-4),在氮气保护下90℃反应10小时,过滤后加入20倍当量氨水,饱和食盐水洗涤三次后无水硫酸钠干燥后以乙醚甲醇重结晶得产物。
第三方面,本发明提供所述通式I化合物或其药学上可接受的盐在制备抑制抗肿瘤药物中的用途。因此,本发明所述的通式I化合物或其药学上可接受的盐可用于治疗肿瘤。
具体实施方式
下面给出的优选实施例,旨在进一步阐明本发明的化合物及其制备方法,而非限定所举例的化合物的范围,也并非限定本发明权利要求中提出的技术方法,即是说通过这些实施例所述的方法可以和很容易地制得通式II、I化合物。对本发明的方法互换或改动,及使用类似原料、试剂和溶剂,对于本专业的普通技术人员是不需要创造性劳动的。本发明所选用的优选案例原料均是采用汉防己甲素(CAS:518-34-3)进行,但并不代表本发明只限于该原料,对于汉防己乙素等如说明书列举的化合物均适合。汉防己乙素购于武汉顶辉化工有限公司,批号:20110913。
实施例1:5-(3,3-二甲基-丁-1-炔基)-汉防己甲素的制备
称取5-溴-汉防己甲素700mg(1mmol)溶于10mlDMSO中,加入CsCO3651.6mg(2mmol、2eq)、3,3-二甲基-1-丁炔(CAS:917-92-0)164mg(2mmol、2eq)、PdCl2(PPh3)221mg(0.03mmol、0.03eq)。在氮气保护下,100℃搅拌反应10小时。反应完毕过滤,加入氨水5ml后再加入30ml乙酸乙酯,饱和食盐水洗涤3次,无水硫酸钠干燥,硅胶柱层析或乙醚∶甲醇(2∶1)重结晶,得5-(3,3-二甲基-丁-1-炔基)-汉防己甲素576mg。收率:82%。
性状:无色针晶。
Figure BDA00002306746900081
5-(3,3-二甲基-丁-1-炔基)-汉防己甲素
C44H50N2O6
MS(ESI):703.35.[M+H]+.
1H NMR(300MHz,CDCl3)δ7.32(d,J=8.1Hz,1H),7.12(dd,J=8.1,2.1Hz,1H),6.84(m,2H),6.79(dd,J=8.2,2.1Hz,1H),6.52(s,1H),6.50(s,1H),6.29(d,J=8.3Hz,1H),6.00(s,1H),3.91(s,3H),3.90-3.86(m,1H),3.80(s,3H),3.79-3.73(m,1H),3.59-3.38(m,2H),3.37(s,3H),3.32-3.17(m,1H),3.16(s,3H),3.04-2.64(m,7H),2.64-2.60(m,1H,overlap),2.63(s,3H),2.58-2.38(m,1H),2.31(s,3H),1.35(s,9H).
13C NMR(101MHz,CDCl3)δ153.83(s),152.86(s),149.38(s),148.39(s),148.28(s),147.10(s),143.64(s),141.62(s),135.07(s),134.71(s),132.64(s),130.82(s),130.11(s),128.11(s),126.11(s),122.82(s),121.97(s),121.92(s),120.41(s),116.27(s),112.27(s),111.59(s),107.08(s),73.08(s),63.83(s),61.43(s),60.59(s),60.42(s),56.15(s),55.53(s),45.23(s),43.73(s),42.59(s),42.21(s),41.57(s),38.17(s),31.22(s),28.46(s),25.25(s),20.65(s).
实施例2:5-(己-1-炔基)-汉防己甲素的制备
称取5-溴-汉防己甲素700mg(1mmol)溶于10mlDMSO中,加入CsCO3651.6mg(2mmol、2eq)、1-己炔(CAS:693-02-7)164mg(2mmol、2eq)、PdCl2(PPh3)235mg(0.05mmol、0.03eq)、BINAP20mg(0.03mmol,0.03eq)。在氮气保护下,100℃搅拌反应10小时。反应完毕过滤,加入氨水5ml后再加入30ml乙酸乙酯,饱和食盐水洗涤3次,无水硫酸钠干燥,硅胶柱层析或乙醚∶甲醇(2∶1)重结晶,得5-(己-1-炔基)-汉防己甲素527mg,收率:75%。
性状:白色无定形粉末。
Figure BDA00002306746900091
5-(己-1-炔基)-汉防己甲素
C44H50N2O6
MS(ESI):703.35.[M+H]+.
1H NMR(300MHz,CDCl3)δ7.34(dd,J=8.3,1.8Hz,1H),7.13(dd,J=8.2,2.5Hz,1H),6.86(s,2H),6.80(dd,J=8.3,2.4Hz,1H),6.53(s,1H),6.51(s,1H),6.30(dd,J=8.3,2.0Hz,1H),6.01(s,1H),3.92(s,3H),3.90-3.82(m,1H),3.79(s,3H),3.73(d,J=9.9Hz,1H),3.64-3.39(m,2H),3.37(s,3H),3.31-3.20(m,1H),3.18(s,3H),3.06-2.66(m,7H),2.63(s,3H),2.49(m,4H),2.30(s,3H),1.65-1.46(m,4H),0.95(t,J=7.2Hz,3H).
13C NMR(101MHz,CDCl3)δ153.84(s),152.95(s),149.38(s),148.38(s),148.28(s),147.12(s),143.63(s),141.63(s),134.99(s),134.64(s),132.64(s),130.95(s),130.12(s),128.03(s),126.09(s),122.84(s),121.99(s),121.93(s),120.34(s),116.23(s),112.28(s),111.71(s),111.59(s),98.61(s),74.47(s),63.83(s),61.45(s),60.74(s),60.35(s),56.15(s),55.50(s),45.20(s),43.79(s),42.55(s),42.24(s),41.56(s),38.08(s),38.08(s),31.09(s),25.23(s),22.02(s),20.86(s),19.52(s),13.65(s).
实施例3:5-(辛-1,7-二炔基)-汉防己甲素的制备
称取5-溴-汉防己甲素700mg(1mmol)溶于10mlDMSO中,加入Ba(OH)2513mg(3mmol、2eq)、1,7-辛二炔(CAS:871-84-1)212mg(2mmol、2eq)、PdCl2(PPh3)235mg(0.05mmol、0.03eq)。在氮气保护下,100℃搅拌反应10小时。反应完毕过滤,加入氨水5ml后再加入30ml乙酸乙酯,饱和食盐水洗涤3次,无水硫酸钠干燥,硅胶柱层析或乙醚∶甲醇(2∶1)重结晶,得5-(辛-1,7-二炔基)-汉防己甲素566mg,收率:75%。
性状:无色针晶。
Figure BDA00002306746900101
5-(辛-1,7-二炔基)-汉防己甲素
C46H50N2O6
MS(ESI):727.35.[M+H]+.
1H NMR(300MHz,CDCl3)δ7.34(dd,J=8.2,2.0Hz,1H),7.13(dd,J=8.1,2.5Hz,1H),6.85(m,2H),6.80(dd,J=8.3,2.5Hz,1H),6.53(s,1H),6.51(s,1H),6.30(dd,J=8.3,2.0Hz,1H),6.01(s,1H),3.92(s,3H),3.88(m,1H),3.79(s,3H),3.76(d,J=10.2Hz,1H),3.58-3.41(m,2H),3.37(s,3H),3.26(m,1H),3.18(s,3H),2.98-2.67(m,7H),2.63(s,3H),2.59-2.39(m,4H),2.31(s,3H),2.29-2.22(m,2H),1.96(t,J=2.6Hz,1H),1.75(m,4H).
13C NMR(75MHz,CDCl3)δ153.69(s),152.84(s),149.26(s),148.30(s),148.22(s),146.98(s),143.46(s),141.52(s),134.97(s),134.55(s),132.53(s),131.40(s),130.88(s),130.01(s),128.00(s),126.08(s),122.69(s),121.88(s),121.83(s),120.21(s),116.10(s),112.14(s),111.44(s),97.65(s),84.06(s),74.84(s),68.42(s),63.68(s),61.30(s),60.68(s),60.24(s),56.03(s),55.38(s),45.07(s),43.60(s),42.47(s),42.11(s),41.45(s),37.92(s),27.78(s),27.46(s),25.18(s),20.73(s),19.24(s),17.89(s).
实施例4:5-(3-环戊烷-丙-1-炔基)-汉防己甲素的制备
称取5-溴-汉防己甲素700mg(1mmol)溶于10mlDMSO中,加入Ba(OH)2513mg(3mmol、2eq)、3-环戊基-1-丙炔(CAS:116279-08-4)216mg(2mmol、2eq)、PdCl2(PPh3)228mg(0.04mmol、0.03eq)BINAP20mg(0.03mmol,0.03eq)。在氮气保护下,100℃搅拌反应10小时。反应完毕过滤,加入氨水5ml后再加入30ml乙酸乙酯,饱和食盐水洗涤3次,无水硫酸钠干燥,硅胶柱层析或乙醚∶甲醇(2∶1)重结晶,得5-(3-环戊烷-丙-1-炔基)-汉防己甲素517mg,收率:71%。
性状:白色无定形粉末。
Figure BDA00002306746900111
5-(3-环戊烷-丙-1-炔基)-汉防己甲素
C46H52N2O6
MS(ESI):729.35.[M+H]+.
1H NMR(400MHz,CDCl3)δ7.37(dd,J=8.2,2.4Hz,1H),δ7.09(dd,J=8.2,2.4Hz,1H),δ7.03(d,J=8.0Hz,1H),δ6.83(d,J=8.0Hz,1H),,δ6.70(dd,J=8.2,2.4Hz,1H),δ6.54(s,1H),δ6.45(d,J=8.0Hz,1H),δ6.26(dd,J=8.2,2.4Hz,1H),δ5.99(s,1H),4.18(dd,J=5.6,11.2Hz,1H),3.92(d,J=8.0Hz,1H),3.86(s,3H),3.75(s,3H),3.68-3.52(m,3H),3.37(s,3H),3.20-3.17(m,1H),3.16(s,3H),3.06-2.8(m,7H),2.80(s,3H),2.55-2.50(m,1H),2.44(d,J=16.0Hz,2H),2.37(s,3H),.2.11(quint,1H),1.84-1.76(m,2H),1.63-1.51(m,4H),1.37-1.21(m,2H).
13C NMR(101MHz,CDCl3)δ153.85(s),153.00(s),149.36(s),148.43(s),148.21(s),147.14(s),143.64(s),141.64(s),134.86(s),134.53(s),132.63(s),130.92(s),130.13(s),127.91(s),127.76(s),125.97(s),122.88(s),121.98(s),121.93(s),120.33(s),116.20(s),112.27(s),111.79(s),111.60(s),98.16(s),74.48(s),63.84(s),61.47(s),60.76(s),60.35(s),56.13(s),55.51(s),45.16(s),43.85(s),42.49(s),42.25(s),41.52(s),40.98(s),39.39(s),38.07(s),32.12(s),25.68(s),25.33(s),25.12(s),20.94(s).
实施例5:5-(环戊基乙炔基)-汉防己甲素的制备
称取5-溴-汉防己甲素700mg(1mmol)溶于10mlDMSO中,加入Ba(OH)2684mg(4mmol、2eq)、环戊基乙炔(CAS:930-51-8)188mg(2mmol、2eq)、PdCl2(PPh3)250mg(0.07mmol、0.03eq)。在氮气保护下,100℃搅拌反应10小时。反应完毕过滤,加入氨水5ml后再加入30ml乙酸乙酯,饱和食盐水洗涤3次,无水硫酸钠干燥,硅胶柱层析或乙醚∶甲醇(2∶1)重结晶,得5-(环戊基乙炔基)-汉防己甲素528mg,收率:74%。
性状:白色无定形粉末。
Figure BDA00002306746900131
5-(环戊基乙炔基)-汉防己甲素
C45H50N2O6
MS(ESI):715.35.[M+H]+.
1H NMR(400MHz,CDCl3)δ7.33(dd,J=8.2,2.1Hz,1H),7.13(dd,J=8.1,2.5Hz,1H),6.95-6.82(m,2H),6.79(dd,J=8.3,2.5Hz,1H),6.53(d,J=0.9Hz,1H),6.51(s,1H),6.30(dd,J=8.3,2.1Hz,1H),6.01(s,1H),3.93(s,3H),3.92-3.86(m,1H),3.80(s,3H),3.76(d,J=10.2Hz,1H),3.57-3.39(m,2H),3.37(s,3H),3.27(dd,J=12.4,5.6Hz,1H),3.18(s,3H),3.04-2.66(m,9H),2.63(s,3H),2.47(d,J=13.6Hz,1H),2.31(s,3H),2.06-1.96(m,2H),1.84-1.72(m,4H),1.65-1.57(m,2H).
13C NMR(101MHz,CDCl3)δ153.83(s),152.85(s),149.38(s),148.38(s),148.25(s),147.12(s),143.64(s),141.63(s),135.03(s),134.66(s),132.64(s),130.87(s),130.11(s),128.07(s),126.09(s),122.83(s),121.98(s),121.93(s),120.37(s),116.24(s),112.28(s),111.74(s),111.59(s),103.09(s),74.06(s),63.84(s),61.45(s),60.69(s),60.38(s),56.15(s),55.51(s),45.22(s),43.78(s),42.58(s),42.23(s),41.56(s),38.12(s),34.21(s),34.20(s),31.28(s),29.70(s),25.26(s),25.00(s),20.76(s).
实施例6:5-(葵-1-炔基)-汉防己甲素的制备
称取5-溴-汉防己甲素700mg(1mmol)溶于10mlDMSO中,加入CsCO3651.6mg(2mmol、2eq)、1-癸炔(CAS:764-93-2)276mg(2mmol、2eq)、PdCl2(PPh3)221mg(0.03mmol、0.03eq)。在氮气保护下,100℃搅拌反应10小时。反应完毕过滤,加入氨水5ml后再加入30ml乙酸乙酯,饱和食盐水洗涤3次,无水硫酸钠干燥,硅胶柱层析或乙醚∶甲醇(2∶1)重结晶,得5-(葵-1-炔基)-汉防己甲素652mg,收率:86%。
性状:白色无定形粉末。
Figure BDA00002306746900141
5-(葵-1-炔基)-汉防己甲素
C48H58N2O6
MS(ESI):759.40.[M+H]+.
1H NMR(400MHz,CDCl3)δ7.34(dd,J=8.2,2.0Hz,1H),7.14(dd,J=8.1,2.5Hz,1H),6.91-6.84(m,2H),6.80(dd,J=8.3,2.5Hz,1H),6.53(d,J=4.4Hz,1H),6.51(s,1H),6.30(dd,J=8.3,2.0Hz,1H),6.01(s,1H),3.92(s,3H),3.91-3.87(m,1H),3.80(s,3H),3.76(d,J=10.4Hz,1H),3.54-3.39(m,2H),3.37(s,3H),3.29-3.21(m,1H),3.18(s,3H),3.04-2.68(m,7H),2.63(s,3H),2.61-2.58(m,1H),2.50(t,J=7.0Hz,2H),2.47-2.36(m,1H),2.31(s,3H),1.68-1.59(m,2H),1.55-1.44(m,2H),1.35-1.26(m,8H),0.88(t,J=6.7Hz,3H).
13C NMR(101MHz,CDCl3)δ153.82(s),152.92(s),149.37(s),148.33(s),148.31(s),147.10(s),143.61(s),141.62(s),135.08(s),134.70(s),132.64(s),130.97(s),130.10(s),128.19(s),128.11(s),126.16(s),122.83(s),121.96(s),121.90(s),120.32(s),116.25(s),112.29(s),111.69(s),111.59(s),98.65(s),74.54(s),63.81(s),61.43(s),60.73(s),60.33(s),56.13(s),55.49(s),45.21(s),43.74(s),42.60(s),42.22(s),41.57(s),38.01(s),31.84(s),29.25(s),29.13(s),29.01(s),28.93(s),25.32(s),22.67(s),20.87(s),19.83(s),14.11(s).
实施例7:5-(3-环己烷-丙-炔基)-汉防己甲素的制备
称取5-溴-汉防己甲素700mg(1mmol)溶于10mlDMSO中,加入CsCO3651.6mg(2mmol、2eq)、3-环己基-1-丙炔(CAS:17715-00-3)244mg(2mmol、2eq)、PdCl2(PPh3)221mg(0.03mmol、0.03eq)。在氮气保护下,100℃搅拌反应10小时。反应完毕过滤,加入氨水5ml后再加入30ml乙酸乙酯,饱和食盐水洗涤3次,无水硫酸钠干燥,硅胶柱层析或乙醚∶甲醇(2∶1)重结晶,得5-(3-环己烷-丙-炔基)-汉防己甲素630mg,收率:85%。
性状:白色无定形粉末。
5-(3-环己烷-丙-炔基)-汉防己甲素
C47H54N2O6
MS(ESI):743.40.[M+H]+.
1H NMR(300MHz,CDCl3)δ7.33(dd,J=8.1,2.3Hz,1H),7.13(dd,J=8.1,2.3Hz,1H),6.84m,2H),6.79(dd,J=8.2,2.2Hz,1H),6.53(s,1H),6.50(s,1H),6.30(dd,J=8.1,2.3Hz,1H),6.01(s,1H),3.92(s,3H),3.91-3.83(m,1H),3.79(s,3H),3.75(d,J=10.1Hz,1H),3.67-3.39(m,2H),3.36(s,3H),3.28-3.22(m,1H),3.18(s,3H),3.03-2.69(m,7H),2.62(s,3H),2.61-2.54(m,1H),2.47(d,J=13.8Hz,1H),2.40(d,J=6.5Hz,2H),2.30(s,3H),1.84-1.46(m,5H),1.32-1.05(m,6H).
13C NMR(101MHz,CDCl3)δ153.80(s),152.96(s),149.37(s),148.32(s),148.26(s),147.09(s),143.59(s),141.63(s),135.08(s),134.69(s),132.62(s),130.92(s),130.10(s),128.19(s),128.11(s),126.15(s),122.81(s),121.95(s),121.90(s),120.32(s),116.23(s),112.28(s),111.78(s),111.57(s),97.44(s),75.34(s),63.81(s),61.41(s),60.74(s),60.33(s),56.13(s),55.50(s),45.22(s),43.76(s),42.60(s),42.24(s),41.56(s),38.03(s),37.68(s),32.77(s),27.68(s),26.32(s),26.18(s),25.31(s),20.93(s).
实施例8:5-(苯乙炔基)-汉防己甲素的制备
称取5-溴-汉防己甲素700mg(1mmol)溶于10mlDMF中,加入CsCO3651.6mg(2mmol、2eq)、苯乙炔(CAS:536-74-3)204mg(2mmol、2eq)、PdCl2(PPh3)221mg(0.03mmol、0.03eq)BINAP20mg(0.03mmol,0.03eq)。在氮气保护下,100℃搅拌反应10小时。反应完毕过滤,加入氨水5ml后再加入30ml乙酸乙酯,饱和食盐水洗涤3次,无水硫酸钠干燥,硅胶柱层析或乙醚∶甲醇(2∶1)重结晶,得5-(苯乙炔基)-汉防己甲素519mg,收率:72%。
性状:无色针晶。
Figure BDA00002306746900161
5-(苯乙炔基)-汉防己甲素
C46H46N2O6
MS(ESI):723.30.[M+H]+.
1H NMR(300MHz,CDCl3)δ7.58-7.49(m,2H),7.39-7.29(m,4H),7.15(dd,J=8.2,2.5Hz,1H),6.86(m,2H),6.81(dd,J=8.3,2.5Hz,1H),6.54(s,1H),6.53(s,1H),6.32(dd,J=8.3,2.1Hz,1H),6.03(s,1H),3.97-3.90(m,4H),3.88(s,3H),3.79(d,J=10.0Hz,1H),3.60-3.43(m,2H),3.40(s,3H),3.33-3.24(m,1H),3.22(s,3H),3.07-2.88(m,4H),2.82-2.68(m,4H),2.65(s,3H),2.50(d,J=13.5Hz,1H).2.34(s,3H).
13C NMR(101MHz,CDCl3)δ153.87(s),153.09(s),149.40(s),149.16(s),148.36(s),147.16(s),143.53(s),141.74(s),135.04(s),134.61(s),132.67(s),131.35(s),131.27(s),130.15(s),128.35(s),128.21(s),128.12(s),128.05(s),126.36(s),123.83(s),122.89(s),122.01(s),121.97(s),120.28(s),116.26(s),112.28(s),111.64(s),110.95(s),97.63(s),83.95(s),63.88(s),61.45(s),61.02(s),60.47(s),56.16(s),55.53(s),45.24(s),43.69(s),42.62(s),42.26(s),41.55(s),38.06(s),25.32(s),20.81(s).
实施例9:5-(1-叔丁基-4-(苯基乙炔基))-汉防己甲素的制备
称取5-溴-汉防己甲素700mg(1mmol)溶于10mlDMSO中,加入CsCO3651.6mg(2mmol、2eq)、4-叔丁基苯乙炔(CAS:772-38-3)316mg(2mmol、2eq)、PdCl2(PPh3)221mg(0.03mmol、0.03eq)。在氮气保护下,100℃搅拌反应10小时。反应完毕过滤,加入氨水5ml后再加入30ml乙酸乙酯,饱和食盐水洗涤3次,无水硫酸钠干燥,硅胶柱层析或乙醚∶甲醇(2∶1)重结晶,得5-(1-叔丁基-4-(苯基乙炔基))-汉防己甲素606mg,收率:78%。
性状:白色无定形粉末。
Figure BDA00002306746900181
5-(1-叔丁基-4-(苯基乙炔基))-汉防己甲素
C50H54N2O6
MS(ESI):779.40.[M+H]+.
1H NMR(300MHz,CDCl3)δ7.48(d,J=8.1Hz,2H),7.41-7.32(m,3H),7.15(d,J=8.2Hz,1H),6.94-6.84(m,2H),6.82(d,J=8.3Hz,1H),6.55(s,1H),6.53(s,1H),6.32(d,J=8.4Hz,1H),6.03(s,1H),3.96(s,3H),4.01-3.91(m,1H,overlap),3.87(s,3H),3.81(d,J=12.6Hz,1H),3.53(m,2H),3.40(s,3H),3.27(m,1H),3.21(s,3H),3.08-2.67(m,8H),2.64(s,3H),2.50(d,J=13.9Hz,1H),2.34(s,3H),1.33(s,9H).
13C NMR(75MHz,CDCl3)δ153.69(s),152.88(s),151.24(s),149.28(s),148.89(s),148.22(s),147.00(s),143.41(s),141.60(s),135.01(s),134.51(s),132.56(s),131.09(s),131.00(s),130.04(s),129.23(s),128.11(s),126.21(s),125.25(s),122.73(s),121.92(s),121.87(s),120.69(s),120.19(s),116.10(s),112.13(s),111.44(s),111.04(s),97.67(s),83.07(s),63.72(s),61.32(s),60.89(s),60.37(s),56.03(s),55.41(s),45.10(s),43.55(s),42.52(s),42.14(s),41.43(s),37.95(s),34.69(s),31.10(s),25.22(s),20.67(s).
实施例10:5-(1-氟-4-(苯基乙炔基))-汉防己甲素的制备
称取5-溴-汉防己甲素700mg(1mmol)溶于10mlDMF中,加入CsCO3651.6mg(2mmol、2eq)、4-氟苯乙炔(CAS:766-98-3)240mg(2mmol、2eq)、PdCl2(PPh3)221mg(0.03mmol、0.03eq)、dppb15mg(0.03mmol、0.03eq)。在氮气保护下,100℃搅拌反应10小时。反应完毕过滤,加入氨水5ml后再加入30ml乙酸乙酯,饱和食盐水洗涤3次,无水硫酸钠干燥,硅胶柱层析或乙醚∶甲醇(2∶1)重结晶,得5-(1-氟-4-(苯基乙炔基))-汉防己甲素488mg,收率:66%。
性状:无色针晶。
Figure BDA00002306746900191
5-(1-氟-4-(苯基乙炔基))-汉防己甲素
C46H45FN2O6
MS(ESI):741.30.[M+H]+.
1H NMR(300MHz,CDCl3)δ7.51(dd,J=8.2,5.5Hz,2H),7.35(dd,J=8.1,2.0Hz,1H),7.15(dd,J=8.1,2.0Hz,1H),7.04(dd,J=8.2,5.5Hz,2H),6.87(s,2H),6.81(dd,J=8.3,2.3Hz,1H),6.54(s,1H),6.53(s,1H),6.33(dd,J=8.3,2.3Hz,1H),6.03(s,1H),3.93(s,3H),3.90(m,1H),3.87(s,3H),3.78(d,J=9.6Hz,1H),3.64-3.42(m,2H),3.40(s,3H),3.27(m,1H),3.21(s,3H),3.02-2.72(m,7H),2.64(s,3H),2.49(d,J=13.7Hz,1H),2.33(s,3H),2.29(m,1H).
13C NMR(101MHz,CDCl3)δ163.64(s),161.16(s),153.92(s),153.08(s),149.40(s),149.14(s),148.45(s),147.20(s),143.55(s),141.75(s),134.80(s),133.22(s),133.14(s),132.65(s),131.19(s),130.16(s),128.02(s),122.89(s),122.04(s),122.01(s),120.28(s),119.91(s),119.88(s),116.19(s),115.75(s),115.53(s),112.25(s),111.63(s),110.81(s),96.48(s),83.55(s),63.88(s),61.47(s),61.02(s),60.46(s),56.16(s),55.52(s),45.14(s),43.76(s),42.48(s),42.27(s),41.50(s),38.06(s),25.15(s),20.86(s).
实施例11:5-(1-甲氧基-4-苯乙炔基)-汉防己甲素的制备
称取5-溴-汉防己甲素700mg(1mmol)溶于10mlDMSO中,加入CsCO3651.6mg(2mmol、2eq)、4-甲氧基苯乙炔(CAS:768-60-5)264mg(2mmol、2eq)、PdCl2(PPh3)221mg(0.03mmol、0.03eq)。在氮气保护下,100℃搅拌反应10小时。反应完毕过滤,加入氨水5ml后再加入30ml乙酸乙酯,饱和食盐水洗涤3次,无水硫酸钠干燥,硅胶柱层析或乙醚∶甲醇(2∶1)重结晶,得5-(1-甲氧基-4-苯乙炔基)-汉防己甲素608mg,收率:81%。
性状:无色针晶。
Figure BDA00002306746900201
5-(1-甲氧基-4-苯乙炔基)-汉防己甲素
C47H48N2O6
MS(ESI):752.30.[M+H]+.
1H NMR(300MHz,CDCl3)δ7.48(s,1H),7.45(s,1H),7.35(dd,J=8.2,2.0Hz,1H),7.15(dd,J=8.2,2.5Hz,1H),6.88(m,4H),6.81(dd,J=8.3,2.5Hz,1H),6.55(s,1H),6.52(s,1H),6.31(dd,J=8.3,2.0Hz,1H),6.02(s,1H),3.95-3.89(m,1H,overlap),3.93(s,3H),3.87(s,3H),3.82(s,3H),3.80-3.76(m,1H),3.691-3.42(m,2H),3.39(s,3H),3.30-3.24(m,1H),2.81(s,3H),3.04-2.69(m,8H),2.64(s,3H),2.52-2.48(m,1H),2.33(s,3H).
13C NMR(101MHz,CDCl3)δ159.51(s),153.84(s),152.87(s),149.40(s),148.87(s),148.34(s),147.14(s),143.55(s),141.72(s),135.08(s),134.64(s),132.77(s),132.67(s),131.02(s),130.14(s),128.19(s),126.31(s),122.87(s),121.99(s),121.94(s),120.29(s),116.24(s),115.97(s),114.01(s),112.30(s),111.61(s),111.26(s),97.61(s),82.50(s),63.84(s),61.45(s),60.96(s),60.45(s),56.16(s),55.52(s),55.31(s),45.22(s),43.69(s),42.61(s),42.24(s),41.54(s),38.01(s),25.33(s),20.82(s).
实施例12:5-((2-吡啶基)-乙炔基)-汉防己甲素的制备
称取5-溴-汉防己甲素700mg(1mmol)溶于10mlDMF中,加入Ba(OH)2684mg(4mmol、2eq)、2-乙炔基吡啶(CAS:1945-84-2)206mg(2mmol、2eq)、PdCl2(PPh3)221mg(0.03mmol、0.03eq)dppb15mg(0.03mmol、0.03eq)。在氮气保护下,100℃搅拌反应10小时。反应完毕过滤,加入氨水5ml后再加入30ml乙酸乙酯,饱和食盐水洗涤3次,无水硫酸钠干燥,硅胶柱层析或乙醚∶甲醇(2∶1)重结晶,得5-((2-吡啶基)-乙炔基)-汉防己甲素376mg,收率:52%。
性状:褐色粉末。
Figure BDA00002306746900211
5-((2-吡啶基)-乙炔基)-汉防己甲素
C45H45N2O6
MS(ESI):724.30.[M+H]+.
1H NMR(400MHz,CDCl3)δ8.59(dd,J=1.2,4Hz,1H),7.67-7.63(ddd,
J=1.2,8,8Hz,1H),7.495(d,J=8Hz,1H),7.42(dd,J=2,8Hz,1H),7.22-7.19(m,1H),7.13(dd,J=2.4,8Hz,1H),7.08(d,J=6.4Hz,1H),6.87(d,J=8Hz,1H),6.80(dd,J=2.4,8Hz,1H),6.59(s,1H),6.47(d,J=2Hz,1H),6.30(dd,J=2.4,8Hz,1H),6.03(s,1H),4.30(dd,J=0.8,15.2Hz,1H),3,98-3.93(m,1H),3.90(s,3H),3.88(s,3H),3.86-3.77(m,2H),3.63-3.48(m,2H),3.43(s,3H),3.32-3.25(m,1H),3.23(s,3H),3.19-2.93(m,5H),2.89(s,3H),2.85(d,J=12Hz,1H),2.68(d,J=14Hz,1H),2.49(s,3H).
13C NMR(101MHz,CDCl3)δ153.86(s),153.67(s),150.12(s),149.81(s),149.39(s),148.32(s),147.15(s),143.97(s),143.43(s),141.68(s),136.05(s),135.00(s),134.53(s),132.66(s),132.02(s),130.14(s),128.23(s),127.02(s),126.38(s),122.87(s),122.48(s),122.03(s),121.99(s),120.19(s),116.18(s),112.24(s),111.60(s),109.98(s),96.84(s),84.12(s),63.86(s),61.43(s),61.20(s),60.48(s),56.15(s),55.49(s),45.16(s),43.57(s),42.56(s),42.23(s),41.50(s),37.99(s),25.29(s),20.81(s).
实施例13:5-苯基-汉防己甲素的制备
称取5-溴-汉防己甲素700mg(1mmol,1eq)溶于10ml 1,4-二氧六环后,加入2M Na2CO3水溶液5ml、苯硼酸(CAS:98-80-6)244mg(2mmol、2eq)、Pd(dppf)Cl2([1,1’-双(二苯基磷)二茂铁]二氯化钯CAS:72287-26-4)25mg(0.03mmol、0.03eq)。在氮气保护下,90℃搅拌反应10小时。反应完毕过滤,加入氨水5ml后再加入30ml乙酸乙酯,饱和食盐水洗涤3次,无水硫酸钠干燥,硅胶柱层析或乙醚∶丙酮(1∶1)重结晶,得5-苯基-汉防己甲素593mg,收率:85%
性状:无色针晶。
Figure BDA00002306746900231
5-苯基-汉防己甲素
C44H46N2O6
MS(ESI):699.35.[M+H]+.
1H NMR(300MHz,CDCl3)δ7.46-7.30(m,5H),7.16(dd,J=8.1,2.5Hz,2H),6.92-6.85(m,2H),6.82(dd,J=8.2,2.3Hz,1H),6.59(d,J=1.4Hz,1H),6.55(s,1H),6.34(dd,J=8.4,2.0Hz,1H),6.06(s,1H),3.95-3.93(m,1H),3.92(s,3H),3.87(d,J=10.5Hz,1H),3.48(d,J=4.8Hz,1H),3.44(s,3H),3.42(s,3H),3.41-3.33(m,2H),3.30(d,J=5.5Hz,2H),3.24(s,3H),3.07-2.70(m,6H),2.64(s,3H),2.55-2.46(m,1H),2.30(s,3H).
13C NMR(75MHz,CDCl3)δ153.70(s),149.32(s),148.98(s),148.33(s),147.56(s),147.01(s),143.77(s),141.69(s),136.94(s),135.04(s),134.68(s),132.54(s),130.07(s),129.83(s),129.62(s),128.28(s),128.00(s),127.84(s),126.84(s),126.69(s),126.02(s),122.77(s),121.87(s),121.84(s),120.23(s),116.05(s),112.62(s),111.46(s),63.75(s),61.78(s),60.59(s),60.06(s),56.04(s),55.62(s),45.15(s),44.61(s),42.54(s),42.08(s),37.88(s),29.60(s),25.24(s),21.18(s).
实施例14:5-(4-甲基苯基)-汉防己甲素的制备
称取5-溴-汉防己甲素700mg(1mmol,1eq)溶于10ml 1,4-二氧六环后,加入2M Na2CO3水溶液5ml、4-甲基苯硼酸(CAS:5720-05-8)272mg(2mmol、2eq)、Pd(dppf)Cl2([1,1’-双(二苯基磷)二茂铁]二氯化钯CAS:72287-26-4)25mg(0.03mmol、0.03eq)dppb15mg(0.03mmol、0.03eq)。在氮气保护下,90℃搅拌反应10小时。反应完毕过滤,加入氨水5ml后再加入30ml乙酸乙酯,饱和食盐水洗涤3次,无水硫酸钠干燥,硅胶柱层析或乙醚∶丙酮(1∶1)重结晶,得5-(4-甲基苯基)-汉防己甲素498mg,收率:70%。
性状:无色针晶。
Figure BDA00002306746900241
5-(4-甲基苯基)-汉防己甲素
C45H48N2O6
MS(ESI)713.35.[M+H]+.
1H NMR(300MHz,CDCl3)δ7.65-7.39(m,2H),7.35(dd,J=8.2,1.9Hz,1H),7.22-7.13(m,3H),6.94-6.77(m,2H),6.82(dd,J=8.3,2.2Hz,1H),6.59(s,1H),6.55(s,1H),6.33(dd,J=8.3,1.9Hz,1H),6.05(s,1H),3.92(s,3H),3.91-3.82(m,2H),3.45(s,3H),3.41(s,3H),3.40-3.27(m,2H),3.23(s,3H),3.03-2.72(m,7H),2.64(s,3H),2.61-2.45(m,2H),2.39(s,3H),2.35(d,J=5.2Hz,1H),2.29(s,3H).
13C NMR(101MHz,CDCl3)δ153.79(s),149.40(s),149.19(s),148.43(s),147.52(s),147.10(s),143.90(s),141.76(s),136.29(s),135.11(s),134.77(s),133.92(s),132.62(s),131.33(s),131.23(s),130.15(s),129.74(s),128.83(s),128.33(s),128.20(s),127.89(s),127.04(s),126.01(s),122.85(s),121.96(s),121.92(s),120.34(s),116.14(s),112.73(s),111.55(s),63.84(s),61.90(s),60.68(s),60.11(s),56.13(s),55.72(s),45.25(s),44.80(s),42.63(s),42.42(s),42.20(s),38.00(s),25.31(s),21.35(s),21.25(s).
实施例15:5-(4-叔丁基苯基)-汉防己甲素的制备
称取5-溴-汉防己甲素700mg(1mmol,1eq)溶于10ml甲苯,加入2MK2CO3水溶液6ml、4-叔丁基苯硼酸(CAS:123324-71-0)272mg(2mmol、2eq)、Pd(dppf)Cl2([1,1’-双(二苯基磷)二茂铁]二氯化钯CAS:72287-26-4)37mg(0.05mmol、0.03eq)。在氮气保护下,90℃搅拌反应10小时。反应完毕过滤,加入氨水5ml后再加入30ml乙酸乙酯,饱和食盐水洗涤3次,无水硫酸钠干燥,硅胶柱层析或乙醚∶丙酮(1∶1)重结晶,得5-(4-叔丁基苯基)-汉防己甲素467mg,收率:62%
性状:白色无定形粉末。
Figure BDA00002306746900251
5-(4-叔丁基苯基)-汉防己甲素
MS(ESI)755.35.[M+H]+.
1H NMR(400MHz,CDCl3)δ7.48(d,J=8.4Hz,1H),δ7.38(d,J=7.2Hz,2H),7.27-7.23(m,1H),7.12-7.10(m,3H),6.88(d,J=8.4Hz,1H),6.80(d,J=8.4Hz,1H),6.60(s,1H),6.51(s,1H),6.32(d,J=8.4Hz,1H),6.06(s,1H),4.34(d,J=6.0Hz,1H),4.18(d,J=9.2Hz,1H),3.88(s,3H),3.70-3.60(m,1H),3.56-3.54(m,2H),3.45(s,3H),3.40(s,3H),3.37-3.27(m,1H),3.23(s,3H),3.12-3.02(m,4H),2.91(s,3H),2.86(d,J=12.0Hz,1H),2.75(d,J=14.0Hz,1H),2.63-2.59(m,2H),2.51(s,3H),1.30(s,9H).
13C NMR(101MHz,CDCl3)δ154.18(s),150.09(s),149.85(s),149.42(s),149.39(s),147.84(s),146.59(s),144.00(s),142.10(s),132.56(s),132.48(s),131.80(s),130.55(s),130.04(s),129.65(s),129.31(s),126.13(s),125.89(s),124.94(s),123.68(s),122.71(s),122.01(s),121.85(s),120.35(s),115.51(s),112.49(s),112.12(s),64.27(s),63.13(s),60.57(s),60.13(s),56.02(s),55.96(s),55.66(s),47.40(s),45.03(s),43.28(s),41.58(s),38.63(s),34.34(s),31.19(s),23.05(s),22.34(s).
实施例16:5-(4-甲氧基苯基)-汉防己甲素的制备
称取5-溴-汉防己甲素700mg(1mmol,1eq)溶于10ml甲苯,加入2MNaOH水溶液6ml、4-甲氧基苯硼酸(CAS:5720-07-0)304mg(2mmol、2eq)、Pd(dppf)Cl2([1,1’-双(二苯基磷)二茂铁]二氯化钯52mg(0.07mmol、0.03eq)、BINAP20mg(0.03mmol,0.03eq)。在氮气保护下,90℃搅拌反应10小时。反应完毕过滤,加入氨水5ml后再加入30ml乙酸乙酯,饱和食盐水洗涤3次,无水硫酸钠干燥,硅胶柱层析或乙醚∶丙酮(1∶1)重结晶,得5-(4-甲氧基苯基)-汉防己甲素560mg,收率:77%。
性状:无色针晶。
Figure BDA00002306746900261
5-(4-甲氧基苯基)-汉防己甲素
C45H48N2O7
MS(ESI)729.30.[M+H]+.
1H NMR(300MHz,CDCl3)δ7.36(dd,J=8.2,2.1Hz,1H),7.15(dd,J=8.2,2.5Hz,2H),6.99-6.85(m,5H),6.82(dd,J=8.4,2.6Hz,1H),6.58(d,J=1.4Hz,1H),6.55(s,1H),6.33(dd,J=8.3,2.1Hz,1H),6.05(s,1H),3.93(s,3H),3.92-3.88(m,1H),3.85(s,3H),3.82(d,J=3.2Hz,1H),3.44(s,3H),3.41(s,3H),3.39-3.24(m,3H),3.23(s,3H),3.07-2.71(m,7H),2.64(s,3H),2.60-2.43(m,2H),2.30(s,3H).
13C NMR(101MHz,CDCl3)δ158.43(s),153.80(s),149.42(s),149.35(s),148.46(s),147.51(s),147.11(s),143.90(s),141.78(s),135.13(s),134.78(s),132.64(s),131.33(s),131.23(s),130.97(s),130.17(s),129.29(s),129.10(s),128.33(s),127.91(s),127.30(s),126.04(s),122.88(s),121.97(s),121.93(s),120.34(s),116.15(s),113.57(s),112.74(s),111.58(s),63.86(s),61.92(s),60.64(s),60.16(s),56.14(s),55.74(s),55.21(s),45.26(s),44.91(s),42.68(s),42.63(s),42.24(s),38.02(s),25.31(s),21.44(s).
实施例17:5-(4-氯基苯基)-汉防己甲素的制备
称取5-溴-汉防己甲素700mg(1mmol,1eq)溶于10ml乙腈,加入2MKOH水溶液6ml、4-氯苯硼酸(CAS:1679-18-1)312mg(2mmol、2eq)、Pd(dppf)Cl2([1,1’-双(二苯基磷)二茂铁]二氯化钯22mg(0.03mmol、0.03eq)。在氮气保护下,90℃搅拌反应10小时。反应完毕过滤,加入氨水5ml后再加入30ml乙酸乙酯,饱和食盐水洗涤3次,无水硫酸钠干燥,硅胶柱层析或乙醚∶丙酮(1∶1)重结晶,得5-(4-氯基苯基)-汉防己甲素454mg,收率:62%。
性状:无色针晶。
Figure BDA00002306746900281
5-(4-氯基苯基)-汉防己甲素
C44H45ClN2O6
MS(ESI)733.30.[M+H]+.
1H NMR(300MHz,CDCl3)δ7.37(m,3H),7.15(m,3H),6.88(m,2H),6.85-6.79(dd,J=8.3,2.4Hz,1H),6.57(s,1H),6.55(s,1H),6.34(d,J=8.3Hz,1H),6.04(s,1H),3.93(s,3H),3.88(m,2H),3.44(s,3H),3.42(s,3H),3.40-3.24(m,3H),3.23(s,3H),3.10-2.69(m,7H),2.65(s,3H),2.51(m,2H),2.29(s,3H).
13C NMR(101MHz,CDCl3)δ153.79(s),149.43(s),149.08(s),148.45(s),147.85(s),147.14(s),143.72(s),141.83(s),135.40(s),135.01(s),134.55(s),132.77(s),132.62(s),131.38(s),130.19(s),128.34(s),128.16(s),127.91(s),126.85(s),126.17(s),122.87(s),122.00(s),121.97(s),120.29(s),116.06(s),112.62(s),111.55(s),63.84(s),61.85(s),60.69(s),60.18(s),56.13(s),55.70(s),45.17(s),44.77(s),42.66(s),42.55(s),42.11(s),37.92(s),29.69(s),25.25(s),21.39(s).
实施例18:5-(4-三氟甲基苯基)-汉防己甲素的制备
称取5-溴-汉防己甲素700mg(1mmol,1eq)溶于10ml二氧六环,加入2M K2CO3水溶液6ml、4-三氟甲基苯硼酸(CAS:128796-39-4)380mg(2mmol、2eq)、Pd(dppf)Cl2([1,1’-双(二苯基磷)二茂铁]二氯化钯22mg(0.03mmol、0.03eq)。在氮气保护下,90℃搅拌反应10小时。反应完毕过滤,加入氨水5ml后再加入30ml乙酸乙酯,饱和食盐水洗涤3次,无水硫酸钠干燥,硅胶柱层析或乙醚∶丙酮(1∶1)重结晶,得5-(4-三氟甲基苯基)-汉防己甲素产物575mg,收率:75%。
性状:白色无定形粉末。
5-(4-三氟甲基苯基)-汉防己甲素
C45H45F3N2O6
MS(ESI)767.30.[M+H]+.
1H NMR(300MHz,CDCl3)δ7.65(s,2H),7.36(m,3H),7.15(dd,J=8.3,2.4Hz,1H),6.87(s,2H),6.74(dd,J=8.3,2.4Hz,1H),6.57(s,1H),6.56(s,1H),6.34(dd,J=8.3,2.4Hz,1H),6.05(s,1H),3.93(s,3H),3.91-3.84(m,1H),3.70(m,1H),3.45(s,3H),3.44(s,3H),3.42-3.27(m,3H),3.24(s,3H),3.10-2.74(m,7H),2.65(s,3H),2.62-2.48(m,2H),2.30(s,3H).
13C NMR(101MHz,CDCl3)δ153.81(s),149.45(s),148.97(s),148.45(s),148.11(s),147.16(s),143.67(s),141.87(s),141.01(s),135.05(s),134.57(s),132.63(s),130.44(s),130.19(s),129.21(s),128.89(s),128.26(s),128.20(s),128.01(s),126.69(s),126.36(s),125.69(s),125.03(s),122.87(s),122.03(s),121.99(s),120.29(s),116.08(s),112.61(s),111.56(s),63.86(s),61.81(s),60.75(s),60.19(s),56.15(s),55.71(s),45.19(s),44.63(s),42.64(s),42.58(s),42.11(s),37.88(s),25.31(s),21.34(s).
实施例19:5-(2-噻吩基)-汉防己甲素的制备
称取5-溴-汉防己甲素700mg(1mmol,1eq)溶于10ml二氧六环,加入三乙胺2ml、2-噻吩硼酸(CAS:6165-68-0)256mg(2mmol、2eq)、Pd(dppf)Cl2([1,1’-双(二苯基磷)二茂铁]二氯化钯22mg(0.03mmol、0.03eq)。在氮气保护下,90℃搅拌反应10小时。反应完毕过滤,加入氨水5ml后再加入30ml乙酸乙酯,饱和食盐水洗涤3次,无水硫酸钠干燥,硅胶柱层析或乙醚∶丙酮(1∶1)重结晶,得5-(2-噻吩基)-汉防己甲素479mg,收率:68%。
性状:黄色无定形粉末。
Figure BDA00002306746900301
5-(2-噻吩基)-汉防己甲素
C42H44N2O6S
MS(ESI):705.25.[M+H]+.
1H NMR(300MHz,CDCl3)δ7.41-7.32(m,2H),7.15(dd,J=8.2,2.5Hz,1H),7.09(dd,J=5.1,3.5Hz,1H),6.91(dd,J=3.4,1.0Hz,1H),6.86(s,2H),6.82(dd,J=8.2,2.4Hz,1H),6.56(s,1H),6.55(s,1H),6.33(dd,J=8.3,2.0Hz,1H),6.04(s,1H),3.93(s,3H),3.86(dd,J=15.0,7.6Hz,2H),3.55(s,3H),3.42(s,3H),3.39-3.24(m,3H),3.22(s,3H),2.86(m,7H),2.64(s,3H),2.56(d,J=13.5Hz,1H),2.30(s,3H),2.28-2.25(m,1H).
13C NMR(101MHz,CDCl3)δ153.79(s),150.44(s),149.43(s),148.49(s),148.47(s),147.12(s),143.67(s),141.82(s),136.97(s),135.05(s),134.60(s),132.62(s),130.17(s),128.86(s),128.20(s),128.04(s),127.46(s),126.74(s),126.15(s),125.55(s),122.87(s),122.01(s),121.98(s),121.63(s),120.31(s),116.08(s),112.53(s),111.56(s),63.87(s),61.80(s),61.03(s),60.14(s),56.13(s),55.71(s),45.21(s),44.74(s),42.66(s),42.60(s),42.09(s),38.01(s),25.28(s),21.21(s).
实施例20:5-(5-甲氧基-2-吡啶基)-汉防己甲素的制备
称取5-溴-汉防己甲素700mg(1mmol,1eq)溶于10ml1,4-二氧六环后,加入2M Na2CO3水溶液5ml、2-甲氧基-5-吡啶硼酸(CAS:163105-89-3)306mg(2mmol、2eq)、Pd(dppf)Cl2([1,1’-双(二苯基磷)二茂铁]二氯化钯25mg(0.03mmol、0.03eq)。在氮气保护下,90℃搅拌反应10小时。反应完毕过滤,加入氨水5ml后再加入30ml乙酸乙酯,饱和食盐水洗涤3次,无水硫酸钠干燥,硅胶柱层析或乙醚∶丙酮(1∶1)重结晶,得5-(5-甲氧基-2-吡啶基)-汉防己甲素430mg,收率:59%。
性状:无色针晶。
Figure BDA00002306746900311
5-(5-甲氧基-2-吡啶基)-汉防己甲素
MS(ESI):730.25.[M+H]+.
1H NMR(300MHz,CDCl3)δ8.01(s,1H),7.53-7.39(m,1H),7.36(d,J=7.5Hz,1H),7.15(d,J=7.4Hz,1H),6.90-6.76(m,4H),6.57(s,1H),6.54(s,1H),6.34(d,J=8.3Hz,1H),6.04(s,1H),3.97(s,3H),3.93(s,3H),3.90-3.78(m,2H),3.46(s,3H),3.41(s,3H),3.39-3.32(m,2H),3.28(d,J=5.2Hz,1H),3.24(s,3H),3.09-2.69(m,7H),2.64(s,3H),2.58(d,J=13.7Hz,2H),2.28(s,3H).
13C NMR(101MHz,CDCl3)δ163.08(s),153.76(s),149.64(s),149.46(s),148.43(s),148.04(s),147.31(s),147.15(s),143.67(s),141.90(s),140.58(s),135.10(s),134.61(s),132.62(s),130.19(s),128.32(s),127.98(s),127.53(s),126.37(s),125.69(s),125.44(s),122.86(s),122.02(s),121.98(s),120.25(s),116.03(s),112.65(s),111.54(s),110.23(s),63.84(s),61.81(s),60.69(s),60.21(s),56.15(s),55.71(s),53.43(s),45.17(s),44.70(s),42.62(s),42.58(s),42.11(s),37.81(s),25.32(s),21.57(s).
实施例21:本发明的双苄基四氢异喹啉类生物碱化合物对多种肿瘤细胞株的抗肿瘤作用
受试肿瘤细胞株包括人肺癌细胞株A549、人肝癌细胞株HepG2、人胃癌细胞株BGC-823。所选用对照品为泰素(紫杉醇)。
样品及对照品制备:将样品溶解于DMSO中,得到浓度为10mg/ml的溶液。再用PBS作梯度稀释,得到浓度分别为1000μg/ml、100μg/ml、10μg/ml、1μg/ml、0.1μg/ml、0.01μg/ml的稀释样品。对照品原液为6mg/ml,用PBS作梯度稀释,得到浓度分别为1000μg/ml、100μg/ml、10μg/ml、1μg/ml、0.1μg/ml、0.01μg/ml的稀释样品。
将稀释好的样品和对照品加入平底96孔板中,每孔10μl,每点作两个平行测试。取处于对数生长期的细胞,细胞经胰酶消化并洗涤后悬浮于含10%血清的DMEM培养基中,并调节细胞悬浮液密度至2×105细胞/ml。在平底96孔板中,每孔加入90μl细胞,最后一孔加入90μl培养基,于37℃、5%CO2细胞培养箱中培养48小时。每孔中加入20μl5mg/mlMTT溶液,继续在培养箱中保温3~4小时。每孔加入100μl溶解液,继续在培养箱中保温过夜,使生成的甲臢晶体充分溶解。测定570nm光吸收值。
通过软件计算样品对各肿瘤细胞的IC50(μg/ml)。
Figure BDA00002306746900331
实验结果表明,本发明化合物除实施例9与实施例20外其余样品在最大浓度100μg/ml时对3种肿瘤细胞的抑制率均在97%以上。对肝癌细胞HepG2实施例5与实施例7化合物活性比紫杉醇更优、对胃癌细胞BGC-823实施例15与实施例19化合物活性比紫杉醇更优。

Claims (16)

1.通式I所示的化合物或其药学上可接受的盐:
Figure FDA00002306746800011
其中:
R1、R2独立地为甲基或氢;
R3、R4独立地为甲氧基、羟基或含1-10个碳原子的直链或支链的烷氧基或酰氧基;
R5独立地为H或含1-20个碳原子的直链或支链的饱和或不饱和的烷基、环烷基、硅烷基、烷氧基或酰氧基,或者为芳香苯环或芳香杂环,其中所述苯环或杂环任选被一个或多个取代基取代;其中所述取代基为含1-20个碳原子的直链或支链的饱和或不饱和的烷基、环烷基、硅烷基、烷氧基或酰氧基或卤素原子;
其中排除R1和R2为CH3或氢;R3为OCH3或OH;R4为OCH3或OH以及R5为H、OH或OCH3的式I化合物及其盐。
2.根据权利要求1所述的化合物或其药学上可接受的盐,其特征在于所述R5独立地为苯乙炔基、3,3-二甲基-丁-1-炔基、己-1-炔基、3-环戊烷-丙-1-炔基、1-氟-4-苯基乙炔基、1-叔丁基-4-苯基乙炔基、(2-吡啶基)-乙炔基、辛-1,7-二炔基、环戊基乙炔基、葵-1-炔基、3-环己烷-丙-炔基、1-甲氧基-4-苯乙炔基、苯基、4-三氟甲基苯基、4-叔丁基苯基、4-甲氧基苯基、4-氯基苯基、4-甲基苯基、2-噻吩基或5-甲氧基-2-吡啶基。
3.根据权利要求1所述的化合物或其药学上可接受的盐,其特征在于通式I中C(1)和C(1’)构型为RR、SS、1S1’R或1R1’S。
4.根据权利要求1所述的化合物或其药学上可接受的盐,其特征在于所述盐选自无机酸组成的盐、有机酸组成的盐或通过碘或溴代烷烃在2和2′位衍生化的季铵盐。
5.根据权利要求4所述的化合物或其药学上可接受的盐,其特征在于所述无机酸选自盐酸、硝酸、硫酸、磷酸或氢溴酸。
6.根据权利要求4所述的化合物或其药学上可接受的盐,其特征在于所述有机酸选自马来酸、富马酸、柠檬酸、酒石酸、乳酸、乙酸、甲磺酸、对甲苯磺酸、己二酸、棕榈酸或单宁酸。
7.制备权利要求1-6任一项所述化合物或其药学上可接受的盐的方法,包括使5-溴代双苄基四氢异喹啉在有机磷配体和碱存在下,利用钯催化剂在有机溶剂中进行Sonogashira偶联或Suzuki偶联反应的步骤。
8.根据权利要求7所述的方法,其特征在于所述有机磷配体选自三苯基膦、1,1′-双(二苯基膦)二茂铁、(±)-2,2′-双-(二苯膦基)-1,1′-联萘或1,4-双二苯基膦丁烷。
9.根据权利要求7所述的方法,其特征在于所述有机磷配体的用量为0.01-1当量。
10.根据权利要求7所述的方法,其特征在于所述钯催化剂选自零价钯或二价钯。
11.根据权利要求7所述的方法,其特征在于所述催化剂的用量为0.01-1当量。
12.根据权利要求7所述的方法,其特征在于所述碱选自碳酸钠、碳酸钾、碳酸铯、氢氧化钠、氢氧化钾、三乙胺或氢氧化钡。
13.根据权利要求7所述的方法,其特征在于所述碱的用量为至少1个当量。
14.根据权利要求7所述的方法,其特征在于所述有机溶剂选自二甲基亚砜、二甲基甲酰胺、四氢呋喃、甲苯、二氧六环或乙腈。
15.根据权利要求7所述的方法,其特征在于所述反应的温度为60-150℃。
16.权利要求1-6任一项所述化合物或其药学上可接受的盐在制备抗肿瘤药物中的用途。
CN201210414509.1A 2012-10-25 2012-10-25 双苄基四氢异喹啉类生物碱及其制备方法和应用 Expired - Fee Related CN103772405B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201210414509.1A CN103772405B (zh) 2012-10-25 2012-10-25 双苄基四氢异喹啉类生物碱及其制备方法和应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201210414509.1A CN103772405B (zh) 2012-10-25 2012-10-25 双苄基四氢异喹啉类生物碱及其制备方法和应用

Publications (2)

Publication Number Publication Date
CN103772405A true CN103772405A (zh) 2014-05-07
CN103772405B CN103772405B (zh) 2016-12-21

Family

ID=50565220

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201210414509.1A Expired - Fee Related CN103772405B (zh) 2012-10-25 2012-10-25 双苄基四氢异喹啉类生物碱及其制备方法和应用

Country Status (1)

Country Link
CN (1) CN103772405B (zh)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103772404A (zh) * 2012-10-25 2014-05-07 上海医药工业研究院 双苄基四氢异喹啉衍生物及其制备方法和应用
WO2016023404A1 (zh) * 2014-08-15 2016-02-18 贵州省中国科学院天然产物化学重点实验室 双苄基异喹啉衍生物、其制备方法及其在肝病的治疗与预防中的用途
CN107033157A (zh) * 2016-02-03 2017-08-11 贵州省中国科学院天然产物化学重点实验室 双苄基异喹啉衍生物及其在制备用于治疗或预防肿瘤的药物中的用途
CN112480140A (zh) * 2020-12-28 2021-03-12 杭州医学院 C5-位取代汉防己甲素衍生物及其制备方法和应用
CN114031623A (zh) * 2021-11-12 2022-02-11 山西医科大学 一种c14位氨基取代粉防己碱衍生物及其制备和应用
CN114933601A (zh) * 2022-06-14 2022-08-23 黄河科技学院 汉防己甲素衍生物及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1293196A (zh) * 2000-09-08 2001-05-02 华西医科大学药物研究所 双苄基异喹啉类生物碱及其制备方法和药物组合物
US6617335B1 (en) * 2002-05-02 2003-09-09 Kanghong Usa, Inc. Preparation and drug composition of bis-benzyl-isoquinoline class alkaloids
CN101735230A (zh) * 2009-11-02 2010-06-16 刘力 双苄基异喹啉衍生物及其制备和用途
CN102875560A (zh) * 2011-07-15 2013-01-16 复旦大学 5-取代粉防己碱类化合物及其在制备抗癌药增敏剂中的用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1293196A (zh) * 2000-09-08 2001-05-02 华西医科大学药物研究所 双苄基异喹啉类生物碱及其制备方法和药物组合物
US6617335B1 (en) * 2002-05-02 2003-09-09 Kanghong Usa, Inc. Preparation and drug composition of bis-benzyl-isoquinoline class alkaloids
CN101735230A (zh) * 2009-11-02 2010-06-16 刘力 双苄基异喹啉衍生物及其制备和用途
CN102875560A (zh) * 2011-07-15 2013-01-16 复旦大学 5-取代粉防己碱类化合物及其在制备抗癌药增敏剂中的用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NING WEI ET AL.: "H1, a derivative of Tetrandrine, exerts anti-MDR activity by initiating intrinsic apoptosis pathway and inhibiting the activation of Erk1/2 and Akt1/2", 《BIOCHEMICAL PHARMACOLOGY》 *
NING WEI ET AL.: "H1, a novel derivative of tetrandrine reverse P-glycoprotein-mediated multidrug resistance by inhibiting transport function and expression of P-glycoprotein", 《CANCER CHEMOTHER PHARMACOL》 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103772404A (zh) * 2012-10-25 2014-05-07 上海医药工业研究院 双苄基四氢异喹啉衍生物及其制备方法和应用
WO2016023404A1 (zh) * 2014-08-15 2016-02-18 贵州省中国科学院天然产物化学重点实验室 双苄基异喹啉衍生物、其制备方法及其在肝病的治疗与预防中的用途
CN107207524A (zh) * 2014-08-15 2017-09-26 贵州省中国科学院天然产物化学重点实验室 双苄基异喹啉衍生物、其制备方法及其在肝病的治疗与预防中的用途
US10189812B2 (en) 2014-08-15 2019-01-29 The Key Laboratory Of Chemistry For Natural Produc Bi-benzyl isoquinoline derivative, preparation method and use thereof in hepatopathy treatment and prevention
CN107033157A (zh) * 2016-02-03 2017-08-11 贵州省中国科学院天然产物化学重点实验室 双苄基异喹啉衍生物及其在制备用于治疗或预防肿瘤的药物中的用途
CN107033157B (zh) * 2016-02-03 2020-05-05 贵州省中国科学院天然产物化学重点实验室 双苄基异喹啉衍生物及其在制备用于治疗或预防肿瘤的药物中的用途
CN112480140A (zh) * 2020-12-28 2021-03-12 杭州医学院 C5-位取代汉防己甲素衍生物及其制备方法和应用
CN114031623A (zh) * 2021-11-12 2022-02-11 山西医科大学 一种c14位氨基取代粉防己碱衍生物及其制备和应用
CN114933601A (zh) * 2022-06-14 2022-08-23 黄河科技学院 汉防己甲素衍生物及其制备方法和应用

Also Published As

Publication number Publication date
CN103772405B (zh) 2016-12-21

Similar Documents

Publication Publication Date Title
CN103772405B (zh) 双苄基四氢异喹啉类生物碱及其制备方法和应用
JP6621486B2 (ja) ピリド−アザヘテロサイクリック化合物及びその製造方法と用途
KR102075697B1 (ko) 피리미딘피롤 화합물, 그 제조 방법, 약학 조성물 및 그 응용
CA2736097C (en) Carbazole compounds for inhibition of nf-kb activity
CN108602823A (zh) 作为去泛素化酶(dub)抑制剂的螺-缩合吡咯烷衍生物
CN109983016B (zh) 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
EP0946554A1 (en) Fused bicyclic pyrimidine derivatives
CA2630465C (en) Antineoplastic compounds
EP3737677B1 (en) Tetrahydroisoquinoline compounds
CN108558835A (zh) 一种氘代azd9291的晶型、制备方法及用途
WO2013178021A1 (zh) 吡咯并[2,1—f][1,2,4]三嗪衍生物及其抗肿瘤用途
WO2017198196A1 (zh) 具有抗肿瘤活性的喹啉衍生物
CN102887904A (zh) 2,3-二氧乙基-5-甲基-8,9-二甲氧基苯并菲啶衍生物及其制备方法和应用
WO2023083194A1 (zh) Wee1蛋白激酶降解剂及其用途
EP3997086A1 (en) Tetrahydroisoquinoline compounds
BR112019027292A2 (pt) composto cíclico semelhante a cumarina como inibidor de mek e uso do mesmo
CZ286180B6 (cs) 6,9-bis(Substituované amino)benzo/g/isochinolin-5 10-diony
JP2013526590A (ja) 縮環キナゾリン誘導体及びその使用
TW201922754A (zh) 新穎之巨環化合物,其製備方法及含彼之藥物組合物
CN105061432B (zh) 6H‑吲哚[2,3‑b]喹喔啉衍生物、药物组合物及其制备和应用
CN108586364B (zh) 一种二苯并氮卓类化合物及其制备方法与应用
CN109476634B (zh) 喹唑啉衍生物的盐的晶体
CN103772404B (zh) 双苄基四氢异喹啉衍生物及其制备方法和应用
CN108774228A (zh) 一类抗肿瘤天然产物ecteinascidins结构类似物的制备和医药用途
Kimura et al. Acridine derivatives. IV. Synthesis, molecular structure, and antitumor activity of the novel 9‐anilino‐2, 3‐methylenedioxyacridines

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20161221

Termination date: 20211025

CF01 Termination of patent right due to non-payment of annual fee